Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK, Lee SH, Kim YJ, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Ahn JS, Im YH, Yu JH, Park YH. Kim HK, et al. Among authors: im yh. BMC Cancer. 2019 Jan 17;19(1):84. doi: 10.1186/s12885-018-5258-9. BMC Cancer. 2019. PMID: 30654765 Free PMC article.
A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
Park J, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim DH, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Park J, et al. Among authors: im yh. Lung Cancer. 2003 Nov;42(2):227-35. doi: 10.1016/s0169-5002(03)00282-4. Lung Cancer. 2003. PMID: 14568691 Clinical Trial.
Extrapulmonary small-cell carcinoma: a single-institution experience.
Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Kim JH, et al. Among authors: im yh. Jpn J Clin Oncol. 2004 May;34(5):250-4. doi: 10.1093/jjco/hyh052. Jpn J Clin Oncol. 2004. PMID: 15231859
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS. Im SA, et al. Among authors: im yh. Oncol Rep. 2005 Aug;14(2):481-7. Oncol Rep. 2005. PMID: 16012734 Clinical Trial.
299 results